<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105958</url>
  </required_header>
  <id_info>
    <org_study_id>TIDALS_01</org_study_id>
    <nct_id>NCT05105958</nct_id>
  </id_info>
  <brief_title>Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>TIDALS</acronym>
  <official_title>Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (TIDALS): a Randomized Placebo-controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly&#xD;
      characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar&#xD;
      muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of&#xD;
      only three to five years. The disease is characterized by pathological accumulations of a&#xD;
      protein called TDP-43, which can be found large cortical and sub-cortical areas of&#xD;
      post-mortem ALS brains.&#xD;
&#xD;
      No causal treatment for this condition is known to date, and there is a large unmet need to&#xD;
      develop new strategies in order to halt or slow down its progression.&#xD;
&#xD;
      The aim of this study is to test the safety and tolerability of Tideglusib, a treatment that&#xD;
      is already in clinical trials for other neuromuscular conditions, in patients with ALS. It is&#xD;
      assumed that this drug may have a significant therapeutic benefit in this population due to&#xD;
      his mode of action: In the ALS mouse model, Tideglusib decreases significantly the amount of&#xD;
      accumulated TDP-43 proteins within the cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Alanine Aminotransferase</measure>
    <time_frame>14 weeks</time_frame>
    <description>Increase in Alanine Aminotransferase &lt; 3x of Upper Limit of Normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most common side effect</measure>
    <time_frame>14 weeks</time_frame>
    <description>Occurence of diarrhea in less then 18 % of patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory outcome: clinical efficacy</measure>
    <time_frame>14 weeks</time_frame>
    <description>Difference of decline in points on the Revised ALS Functional Rating Scale between the two study arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcome: vital capacity</measure>
    <time_frame>14 weeks</time_frame>
    <description>slow vital capacity in %</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Tideglusib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1000 mg Tideglusib once daily per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo matching Tideglusib 100 mg once daily per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tideglusib</intervention_name>
    <description>1000 mg/day per os</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tideglusib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Possible, probable (clinically or laboratory supported) or definite ALS according to&#xD;
             the revised version of the El Escorial criteria&#xD;
&#xD;
          -  Disease duration &lt; 18 months&#xD;
&#xD;
          -  Vital capacity of more than 60% of normal (defined as slow vital capacity, best of&#xD;
             three measurements)&#xD;
&#xD;
          -  Age more than 18 years&#xD;
&#xD;
          -  On a stable dose of riluzole for at least four weeks or not taking riluzole&#xD;
&#xD;
          -  On a stable dose of edaravone for at least four weeks or not taking edaravone&#xD;
&#xD;
          -  Capable of thoroughly understanding all information given and giving full informed&#xD;
             consent according to GCP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous participation in another clinical study within the preceding 12 weeks&#xD;
&#xD;
          -  Proven SOD1- or FUS - mutation&#xD;
&#xD;
          -  Tracheostomy or assisted ventilation of any type during the preceding three months&#xD;
&#xD;
          -  Pregnancy or breast-feeding females&#xD;
&#xD;
          -  Any medical condition known to have an association with motor neuron dysfunction which&#xD;
             might confound or obscure the diagnosis of ALS&#xD;
&#xD;
          -  Presence of any concomitant life-threatening disease or impairment likely to interfere&#xD;
             with functional assessment&#xD;
&#xD;
          -  Evidence of a major psychiatric disorder or clinically evident dementia precluding&#xD;
             evaluation of symptoms&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Cardiovascular disorder/arrhythmia&#xD;
&#xD;
          -  Impaired kidney function, defined as creatinine levels of 2.5 x upper limit of normal&#xD;
             (ULN)&#xD;
&#xD;
          -  Impaired liver function, defined as aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) of 3 x ULN&#xD;
&#xD;
          -  Liable to be not cooperative or comply with trial requirements as assessed by the&#xD;
             investigator, or unable to be reached in the case of emergency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemarie Hübers</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annemarie Hübers</last_name>
    <phone>0795531171</phone>
    <email>annemarie.hubers@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier Scheidegger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Annemarie Hübers</last_name>
      <phone>0795531171</phone>
      <email>annemarie.hubers@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>David Benninger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint-Gall</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Markus Weber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans Jung</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Annemarie Hübers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

